Maravai LifeSciences Holdings Inc. Class A Common Stock vs Roblox Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Roblox Corp trades at $47 (market cap $35.37B). The key difference: Roblox Corp is far larger — about 36.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Roblox Corp for 94 Days on average.
| MRVI | RBLX | |
|---|---|---|
Market Cap | $972.90M | $35.37B |
Volume | 4,325,710 | 6,569,814 |
Sector | Health | Technology |
52-Week High | $9.00 | $138.56 |
52-Week Low | $2.83 | $35.54 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $1.08B | $34.19B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Roblox (RBLX) trades at $47.54, down 4.13% today amid mixed technical signals and analyst concerns about bookings growth. The stock shows strong revenue growth (2025: $4.89B, up 36% year-over-year) but remains unprofitable with a -17.61% net margin. Recent technical analysis indicates bullish moving averages but neutral oscillators, with key resistance at $50-$52. The company continues to beat earnings expectations, with Q2 2026 EPS of -$0.26 beating estimates by 24%.
Investment outlook balances strong user engagement and AI-driven creator tools against persistent profitability challenges. Analyst consensus sits at $51.35 with 42% buy ratings, though recent Jefferies downgrade to Underperform highlights concerns about valuation sustainability. Key risks include decelerating bookings growth and high P/B ratio of 232.69, while opportunities lie in AI-powered platform expansion and $3 billion buyback program.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →